Neoadjuvant PD-1 Blockade in Resectable Merkel Cell Carcinoma
Clinical trial NCT05496036 · RECRUITING
Trial details
- NCT number
- NCT05496036
- Sponsor
- Abramson Cancer Center at Penn Medicine
- Status
- RECRUITING
- Phase
- Phase 2
- Study type
- INTERVENTIONAL
- Start date
- 2023-02-13
- Primary completion
- 2026-12-31
- Enrollment
- 15
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.